Suicide prevention is at a crossroads in the United States. According to the latest CDC reports, nearly 11 million people in the U.S. had thoughts of suicide in 2018. And over 1.4 million Americans attempted suicide that same year.
As the number of suicide deaths and attempts increases, early identification, assessment, and effective treatments are more important than ever. But rising case numbers also make it increasingly difficult to implement these strategies across already strained healthcare networks, and access to suicide assessment and treatment training is sometimes difficult to access and disseminate.
That’s why we’re proud to announce a new partnership between CAMS (Collaborative Assessment and Management of Suicidality) and NeuroFlow, a healthcare solution that combines workflow automation, an engagement platform, and applied AI to simplify remove patient monitoring, deliver risk stratification, and facilitate collaborative care.
This effort combines CAMS’s evidence-based Suicide Prevention Training therapeutic framework with Neuroflow’s industry-leading remote monitoring and behavioral health platform.
Through this partnership, clinicians across the country will have access to timely, customizable, and scalable tools to help identify, assess, track, engage, and treat a growing population of diverse individuals at risk of suicide.
Can Technology Help Prevent Suicides?
In recent years, remote monitoring tools and measurement-based care (MBC) have emerged as valuable parts of suicide prevention and treatment strategies. However, too many gaps currently exist in many suicide prevention programs, most notably:
- Early and accurate detection of suicidal ideation
- Customized care designed for diverse patient populations
- Smarter assessment, planning, engagement tools
- Challenges with providing assessment and care in rural areas with limited access
- Resilient user-centric support networks that bridge in-person clinical care
These are precisely the gaps that CAMS and NeuroFlow aim to fill with this strategic partnership. “NeuroFlow provides a unique opportunity to identify patients at risk for self-harm and suicide proactively,” notes Matt Miclette, Neuroflow’s Director of Clinical Operations. “However, there is simply no replacement in digital health for skilled professionals trained in evidence-based modalities such as CAMS.”
“We’re particularly excited about how this partnership will increase the use of the Suicide Status Form,” says Andrew Evans, President and CEO of CAMS-care. “Neuroflow’s platform will go a long way in enabling and encouraging collaboration between clients and clinicians, which has always been a cornerstone of the CAMS-care system.”
An Evidence-Based Approach to Suicide Prevention
CAMS-care pioneered one of the few evidence-based protocols for the initial assessment and treatment of suicidality in use today. NeuroFlow is an industry leader in collaborative care with smart tools that not only track patient progress, and identify trends, they increase user engagement—an often underserved step in suicide prevention programs.
The combination of proven suicide prevention solutions with smarter tracking and data-driven care gives clinicians access to specialist-grade assessment tools, making it easier to identify, engage, and track the progress of patients that have thoughts of self-harm in suicide prevention treatments across their entire network.
Even better, this platform provides a flexible, scalable approach that can be tailored across theoretical orientations and disciplines for a wider range of suicidal patients across clinical settings and different treatment modalities.
Learn more about how NeuroFlow and CAMS are working together to supply clinicians with clinical-grade assessment tools, data-driven care resources, unparalleled smart tracking tools, and an easy-to-use online platform that is closing the assessment and treatment gap for all modalities of suicide prevention.